Browse the evidence

Insulin resistance in skeletal muscle is driven by intramuscular lipid accumulation interfering with insulin signaling, rather than by increased fat oxidation inhibiting glucose metabolism via the Randle cycle.

Insulin resistance in muscle is not caused by your body's ability to burn fat. Instead, it is linked to the buildup of specific fat molecules (like diacylglycerol and ceramide) inside muscle cells that block insulin signals. This happens when lipid accumulation exceeds the muscle's ability to oxidize or store it safely, often seen in obesity and type 2 diabetes. Focus on improving metabolic flexibility and reducing intramuscular lipid accumulation rather than fearing fat oxidation.

Ectopic lipid accumulation in the liver and skeletal muscle is a primary cause of insulin resistance, mediated by lipid metabolites like diacylglycerol (DAG) and ceramides which interfere with insulin signaling pathways.

Focus on reducing fat stored in your liver and muscles, not just overall weight. This can be achieved through modest weight loss, exercise, or specific medical treatments for conditions like NAFLD. Reducing intrahepatic triglycerides dramatically reverses insulin resistance.

Diacylglycerol (DAG) accumulation at the plasma membrane, specifically the sn-1,2 stereoisomer, activates Protein Kinase C (PKC) isoforms (PKCε in liver, PKCθ in muscle), which inhibits insulin signaling.

Not all fat is bad for insulin signaling. It is the specific type and location of fat (DAG at the cell membrane) that blocks insulin. Reducing this specific lipid fraction improves sensitivity.

Sleep restriction (4 hours/night) increases evening cortisol levels and delays the nocturnal nadir, while simultaneously decreasing TSH levels and amplitude, indicating a disruption of the hypothalamo-pituitary-adrenal and thyroid axes.

Short sleep doesn't just make you tired; it shifts your stress hormones (cortisol) to be higher in the evening and lowers thyroid-stimulating hormone (TSH). This hormonal imbalance contributes to metabolic stress. Prioritizing 8 hours of sleep helps normalize these rhythms.

High body-mass index (BMI ≥25 kg/m²) is causally associated with an increased global burden of cancer, accounting for 3.6% of all new adult cancer cases in 2012, with the highest attributable fractions found in women and high human development index countries.

Maintaining a healthy body weight is a critical, modifiable factor in reducing your risk of several common cancers, particularly breast, colon, and endometrial cancers. This is not just about aesthetics; it is a direct public health measure. Aim for a BMI between 20-25 kg/m², as risk increases continuously with higher BMI values, even within the 'normal' range. This is especially important for women, who face a higher attributable fraction of cancer cases from high BMI compared to men.

Altered muscle composition, specifically lower muscle attenuation (indicative of intramuscular fat), is a strong independent marker of insulin resistance, particularly in obese individuals.

For those who are obese, the quality of your muscle matters as much as its size. Lower muscle density (attenuation) on CT scans, which reflects higher intramuscular fat, is a strong predictor of insulin resistance. Prioritize exercises and nutrition that improve muscle quality and reduce intramuscular fat, not just increasing muscle size.

Long-term hormone replacement therapy (estrogen/progestin) in postmenopausal women delays atherosclerosis and bone loss but increases the risk of breast cancer, with no clear impact on life expectancy.

For postmenopausal women, Hormone Replacement Therapy (HRT) is a trade-off: it significantly protects bones and heart health but increases breast cancer risk and does not extend life. The decision should be personalized based on individual risk factors, family history, and attitude toward treatment, rather than applied universally.

Peripheral ghrelin increases food intake by binding to GHSR receptors in the ventral tegmental area (VTA), thereby increasing dopamine neuron firing rates and synaptic plasticity.

This research highlights that hunger is driven by a specific hormonal signal (ghrelin) that directly activates your brain's reward system (VTA). Understanding this biological mechanism can help shift the perspective from 'willpower' to managing biological signals, such as through scheduled eating or managing environmental cues that trigger these pathways.

Blocking GHSR receptors in the VTA attenuates rebound feeding after fasting and blunts the feeding response to restricted feeding schedules.

This finding suggests that the brain's reward system, specifically the VTA, plays a critical role in the 'catch-up' eating that happens after fasting. Blocking this specific pathway can reduce the intense urge to eat after a fast, highlighting the importance of the brain's reward circuitry in appetite regulation.

Obesity-induced chronic low-grade inflammation in adipose tissue acts as a causal mechanism for insulin resistance and type 2 diabetes mellitus.

In obesity, fat tissue doesn't just store energy; it actively releases inflammatory signals that block insulin from working. This inflammation is a key driver of type 2 diabetes risk. While weight loss helps, the inflammatory state itself is a direct cause of metabolic dysfunction, suggesting that managing inflammation is crucial for metabolic health.

Elevated levels of the transcriptional coactivator PGC-1α protect skeletal muscle from atrophy by suppressing the transcriptional activity and binding of the FoxO3 transcription factor to atrophy-related genes (atrogin-1 and MuRF-1).

To maintain muscle mass, especially during periods of stress, illness, or reduced activity, prioritize metabolic health and regular movement. This helps keep PGC-1α levels high, which naturally blocks the molecular signals (FoxO3) that trigger muscle breakdown. While this doesn't replace resistance training for growth, it is a critical defense against muscle loss.

Acute or intermittent administration of the flavonoid fisetin acts as a senolytic to clear senescent cells, thereby reducing age-related pathology and extending both healthspan and lifespan in aged mice.

Fisetin is a potent senolytic that extends healthspan and lifespan in mice when administered intermittently at high doses (e.g., 100 mg/kg body weight for 5 days). While human trials are beginning, current evidence supports an intermittent 'hit-and-run' dosing strategy rather than daily supplementation to maximize efficacy and minimize potential side effects. Consult a physician before starting high-dose supplementation.

High intrahepatic triglyceride (IHTG) content, rather than visceral adipose tissue (VAT) volume, is the primary independent marker and driver of metabolic complications (insulin resistance and dyslipidemia) in obesity.

If you are obese, your liver fat content is a more critical indicator of your metabolic health than your waist size. While reducing visceral fat is good, strategies that specifically target liver fat accumulation (such as reducing fructose intake or alcohol, and improving insulin sensitivity) may yield better metabolic outcomes than focusing solely on waist circumference reduction.

Dietary supplements containing ephedra alkaloids pose a serious health risk, causing adverse cardiovascular and central nervous system events including hypertension, stroke, seizures, and death, even in previously healthy individuals at low doses.

Avoid dietary supplements containing ephedra alkaloids (ma huang). These products have been linked to heart attacks, strokes, seizures, and death, even in healthy people taking low doses. The potential for severe, permanent injury or fatality outweighs any unproven weight loss or energy benefits.

Adipokines, specifically leptin and adiponectin, play opposing roles in cancer development, with leptin promoting tumor growth and adiponectin offering protection.

Obesity alters hormone secretion from fat cells: it increases leptin (which fuels cancer) and decreases adiponectin (which protects against cancer). Weight loss helps restore this balance.

Obesity promotes aggressive breast cancer behavior (growth, invasion, metastasis) through a mechanism involving hypoxia-induced inflammation, increased aromatase expression, and stimulation of cancer stem cells.

Weight loss interventions aim to break the cycle of obesity-driven inflammation and estrogen production, thereby reducing the fuel for tumor growth and metastasis.

Obesity is associated with an increased risk of triple-negative breast cancer (TNBC) in premenopausal women, whereas this association is null or inverse in postmenopausal women.

For premenopausal women, obesity specifically increases the risk of the more aggressive triple-negative breast cancer subtype. Weight management is particularly crucial in this demographic.

Higher birth weight is directly associated with higher attained Body Mass Index (BMI) in later life, indicating that fetal growth patterns program long-term adiposity risk.

Your body's fat storage set point may be influenced by your growth in the womb. While you cannot change your birth weight, understanding this link highlights why early childhood nutrition and avoiding excessive fetal growth (in diabetic pregnancies) are critical for preventing adult obesity.

Lower birth weight is inversely associated with central (abdominal) obesity and metabolic syndrome risk after adjusting for attained adult BMI, creating a 'small baby, high BMI' phenotype with elevated cardiovascular risk.

If you were born small but became overweight as an adult, your risk for heart disease and diabetes is significantly higher than someone who was born larger and became overweight. Focus on preventing childhood obesity and managing abdominal fat, as this specific combination is a major driver of metabolic syndrome.

High glucose levels independently regulate gene expression through the transcription factor ChREBP, which is activated by glucose metabolites (xylulose 5-phosphate) to promote lipogenesis and glycolysis, even in the absence of insulin.

High carbohydrate intake directly signals your liver and fat cells to produce fat and break down glucose for energy, independent of insulin levels, via a specific protein (ChREBP).

Fasting and low glucose levels trigger transcriptional changes that promote gluconeogenesis and fatty acid oxidation via the activation of transcription factors like CREB, PGC1, and PPARs, counteracting insulin's effects.

When you fast, your body switches to producing glucose and burning fat by turning on specific genes (via CREB and PGC1). This is a natural survival mechanism.

Testosterone replacement therapy significantly decreases serum leptin levels in older hypogonadal men, suggesting a hormonal modulation of adiposity regulation.

Testosterone therapy in hypogonadal men has been shown to lower leptin levels, a hormone involved in regulating body fat and hunger. This suggests testosterone may help modulate body composition, although this study did not show significant changes in body fat percentage or BMI.

Visceral adipose tissue (VAT) volume is independently associated with systemic inflammation and oxidative stress, even after adjusting for overall obesity measures like BMI and waist circumference.

If you are concerned about inflammation, focusing solely on total body weight (BMI) is insufficient. Visceral fat, located deep in the abdomen, is a stronger predictor of inflammatory markers like CRP and IL-6 than subcutaneous fat. While you cannot directly 'target' visceral fat loss with spot-reduction exercises, general weight loss and exercise tend to reduce visceral fat effectively. Monitoring waist circumference may be a more practical proxy for visceral fat risk than BMI alone.

Insulin resistance drives nonalcoholic fatty liver disease (NAFLD) progression through increased free fatty acid flux from adipose tissue to the liver, leading to hepatic triglyceride accumulation and impaired glucose metabolism.

Fatty liver is fundamentally a metabolic disorder driven by insulin resistance, not just a result of eating too much fat or sugar. Even lean people can develop it. Treating the underlying insulin resistance (e.g., through exercise, weight management, or medication) is key to managing the liver disease, rather than just focusing on liver-specific diets.